High risk populations are eligible for the shots for now, and the general population will have to wait until the end of the ...
Novavax (NASDAQ:NVAX), the biotech behind the Nuvaxovid COVID-19 shot, was no exception. Following an over 26-fold rise in ...
Currently, the KP.3 and KP.3.1.1 FLiRT variants, derivatives of KP.1 and KP.2, are the most prevalent in Canada and the ...